Growth Opportunities in Obesity Drugs and Delivery Platforms

Description

GLP-1-based Drugs, Along With Injector and Nanomaterial Delivery Platforms, Drive Transformational Industry Growth

The increasing disposable incomes in developing countries have contributed to a sedentary lifestyle worldwide. The advent of food delivery apps has also increased accessibility to various culinary delights. These factors have contributed mainly to obesity and other lifestyle diseases.

People with a body mass index (BMI) of more than or equal to 30 (or 27kg/m2) are classified as obese and may or may not have co-morbidities. Obesity is also known to increase the risk of several diseases, such as type 2 diabetes, cancer mortality, overall mortality, and cardiovascular disorders. It also worsens the prognosis of several diseases and other related co-morbidities.

An active lifestyle with healthy eating practices is crucial for maintaining optimal BMI. Dietary supplementation with fibers, vitamins, minerals, probiotics, and other nutrients can also help manage weight. In addition, healthcare professionals are exploring behavioral interventions for obesity management. Bariatric surgery is the gold standard for obesity treatment. However, recent therapeutic advancement has enabled the launch of oral and injectable drugs for weight loss. GLP-1-based obesity treatments are fast emerging as potent treatment options for obesity and have a favorable safety profile.

In this study, Frost & Sullivan analyzes the emerging and recently approved obesity treatment pipelines and associated advances in drug delivery technologies. We also provide insights into funding, the collaborative landscape of obesity treatments and delivery platforms, the clinical trial landscape for obesity management, and the mechanism of action of promising anti-obesity drug candidates.

Product Code: DAD6

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Obesity Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology

Growth Opportunity Analysis

Overview of Noncommunicable Diseases (NCDs)
Scope
Segmentation
Growth Drivers
Growth Restraints

Obesity Drugs: Pipeline Analysis

Overview of Approved Obesity Drugs
Game Changers for Obesity Management
Addressing the Challenges of Blockbuster Obesity Drugs
Overview of the Obesity Clinical Trial Landscape
Pipeline Analysis of Obesity Drugs
Regulatory Landscape Overview for Anti-Obesity Drugs: The United States and Europe
Major Emerging GLP-based Dual Receptor Agonists
Major Emerging GLP-based Obesity Drugs in Phase 2 and 3 Clinical Trials
Snapshot of Emerging Non-GLP Obesity Drugs

Drug Delivery Innovations

Overview of Drug Delivery Innovations
Features of Drug Delivery Innovations
Snapshot of Emerging Drug Delivery Innovations: Injector Platforms
Snapshot of Emerging Drug Delivery Innovations: Nanomaterial Platforms

Obesity Drugs and Delivery Platforms: Acquisitions, Partnerships, and Funding

Acquisitions by Large Pharma Companies
Pharma Collaborations
Overview of the Funding Landscape for Obesity Drug Delivery
Snapshot of the Partnership Landscape for Obesity Drug Delivery

Obesity Outlook

A Multipronged Approach to Obesity Management
The Future of Drug Delivery Platforms for Obesity Management

Growth Opportunity Universe

Growth Opportunity 1: GLP-1-based Multi-agonists
Growth Opportunity 2: Individualized Treatment Strategy
Growth Opportunity 3: The Use of Needle-free Drug Delivery Technologies

Next Steps

Your Next Steps
Why Frost, Why Now?
Legal Disclaimer